Natixis Advisors, L.P. Cytokinetics Inc Transaction History
Natixis Advisors, L.P.
- $53.5 Billion
- Q4 2024
A detailed history of Natixis Advisors, L.P. transactions in Cytokinetics Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 33,659 shares of CYTK stock, worth $1.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,659
Previous 37,595
10.47%
Holding current value
$1.5 Million
Previous $1.99 Million
20.25%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CYTK
# of Institutions
396Shares Held
114MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$654 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$531 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$479 Million0.31% of portfolio
-
State Street Corp Boston, MA6.17MShares$275 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.84MShares$127 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.19B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...